We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Panel of Genetic Loci Accurately Predicts Risk of Developing Gout

By LabMedica International staff writers
Posted on 14 Oct 2019
A large GWAS (genome-wide association study) highlighted genetic loci associated with the metabolic regulation of serum levels of uric acid (urate) and identified a panel of 183 loci linked to the risk of developing gout.

Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen, and hydrogen with the formula C5H4N4O3. More...
It forms ions and salts known as urates and acid urates, such as ammonium acid urate. Uric acid is a product of the metabolic breakdown of purine nucleotides, and it is a normal component of urine. High blood concentrations of uric acid can lead to gout and are associated with other medical conditions, including diabetes and the formation of ammonium acid urate kidney stones.

As part of a major effort to develop screening tests for gout risk as well as potential new treatments for the disorder, investigators at Johns Hopkins University (Baltimore, MD, USA) performed a trans-ancestry genome-wide association study of serum urate in 457,690 individuals participating in 74 studies. The experimental cohort included 288,649 people of European ancestry, 125,725 people of East Asian ancestry, 33,671 African Americans, 9,037 South Asians, and 608 Hispanics.

Results of the analysis identified 183 loci where DNA variations were strongly linked to high serum urate levels, of which only 36 had been found in prior studies. The investigators developed a risk scoring system from the panel of 183 loci, which they used to assess the gout risk in an independent sample of 334,880 people from a medical research database. They found that the panel of 183 loci accurately stratified the participants according to their risk of developing gout. The prevalence of gout in the 3.5% of individuals in the three highest risk score categories was more than three times greater than that of those in the most common risk score category.

Further mining of the data enabled the investigators to map the 183 loci to specific genes. Many of these genes normally were active in the kidneys, urinary tract, and liver, which were expected considering the roles of the kidneys and liver in regulating serum urate levels.

“These genetic variants we highlighted can now be studied further to identify how they contribute to high urate levels, and to determine whether they would be good targets for treating gout,” said first author Dr. Adrienne Tin, assistant scientist in epidemiology at Johns Hopkins University. “These findings may be useful in developing screening tests for gout risk so that patients who are at risk can adopt dietary changes to avoid developing the condition. The urate-related gene variants and biological pathways uncovered here also should be useful in the search for new ways to treat gout.”

The study was published in the October 2, 2019, issue of the journal Nature Genetics.

Related Links:
Johns Hopkins University


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Myocardial Infarction Test
Quidel Triage Cardio3 Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.